What Maravai LifeSciences Holdings, Inc. told the SEC could break it.

Maravai's results are exposed to volatile, concentrated end-market demand: high-volume sales of its proprietary CleanCap analogs for commercial-phase vaccine programs and related services represented approximately 21.0% (2023) and 25.4% (2024) of total revenues, but 0.0% in 2025 following the end of the COVID-19 pandemic, and it expects to continue experiencing unpredictable fluctuations in high-volume CleanCap demand; this dependence on a small set of large vaccine programs makes revenue lumpy and hard to forecast.

“For the years ended December 31, 2025, 2024 and 2023, we estimate that revenue from high-volume sales of CleanCap ® for commercial phase vaccine programs and related services represented approximately 0.0%, 25.4% and 21.0%, respectively, of our total revenues.”

Maravai relies on a limited number of suppliers, and in some cases sole suppliers, for key raw materials: a proprietary DNA reagent, certain packaging materials, specific cell lines for Cygnus operations, certain raw materials used in its TriLink products, and the raw materials sold under the Glen Research brand are sole sourced; delays or difficulties in securing these materials — amid ongoing global supply-chain, logistics and ocean-freight constraints — could interrupt its production operations if it cannot obtain an acceptable substitute.

“Certain of our raw materials are sourced from a limited number of suppliers and some materials, including a proprietary DNA reagent, certain packaging materials, specific cell lines for Cygnus operations and certain raw materials used in our TriLink products, as well as those raw materials sold under the Glen Research brand, are sole sourced.”

Maravai depends on a limited number of customers for a high percentage of its revenue, and its results depend on maintaining those relationships; as a supplier of mRNA reagents, CleanCap analogs and bioprocess-testing products to biopharma manufacturers, the loss of, reduced ordering by, or pricing pressure from one of these concentrated (undisclosed) customers could materially and adversely affect its revenue and profitability.

“Our dependency on a limited number of customers for a high percentage of our revenue and our ability to maintain our current relationships with such customers.”

Maravai's TriLink and Cygnus products — materials used in research and biopharmaceutical production, clinical-trial vaccines and vaccine support, and impurity-detection assays used in regulatory approval — may be subject to extensive and rigorous regulation by the FDA and other federal, state, local and foreign authorities; the risk that its products become subject to more onerous regulation, or that it fails quality/audit and compliance requirements, could raise costs, disrupt production and limit its addressable use cases.

“Our products and operations may be subject to extensive and rigorous regulation by the FDA and other federal, state, or local authorities, as well as foreign regulatory authorities.”